Anaerobutyricum soehngenii as Next Generation Probiotics
Background A. soehngenii and Diseases Services Products Brochures FAQs Resources
Introduction of Anaerobutyricum soehngenii (A. soehngenii)
A deeper understanding of the gut microbiota and its role is essential for future healthcare strategies. In this regard, extensive study of the potential use of selected probiotic bacteria species and their strains is desperately needed for the prevention and treatment of numerous human and animal diseases. At Creative Biolabs, we team up with you to understand your needs. Our experienced R&D team provides you with the support you need during live biotherapeutic products (LBP) development.
Introduction of Anaerobutyricum soehngenii (A. soehngenii)
A. soehngenii is an anaerobic Gram-positive, catalase-negative bacterium belonging to the clostridial cluster XIVa of the phylum Firmicutes. A. soehngenii has bile acid sodium transporter and choloylglycine hydrolase genes, so it can affect the host bile acid metabolism. It can produce both propionate and butyrate, metabolites that have been shown to have a positive effect on gut and overall health. The type strain, L2-7T, was isolated from human infant faeces. The DNA G+C content of the type strain is 38.6 mol%.
A. soehngenii for Disease Treatment
The potential next-generation probiotics with good prospects for improving T2DM have attracted increasing attention, such as Akkermansia muciniphila, A. soehngenii and Parabacteroides distasonis. The beneficial effects of these next-generation probiotics include improving insulin sensitivity, reducing inflammation and weight gain, and improving glucose homeostasis by producing short-chain fatty acids or secondary bile acids. In addition, oral treatment with A. soehngenii species had a modest blood pressure lowering effect in humans.
In a db/db mouse model, live cells of A. soehngenii L2-7T were found to increase insulin sensitivity and affect intestinal and liver gene expression. A recent study showed that a single duodenal administration of A. soehngenii L2-7T affected gene expression in the duodenum, stimulated the secretion of GLP-1, and improved insulin sensitivity. These results altogether showed that A. soehngenii L2-7T had great potential to serve as a next-generation therapeutic product for people that are at risk of developing type 2 diabetes and showed increased levels of insulin resistance.
Fig.1 Causal relationship between A. soehngenii and obesity.1
What Services Can We Provide for A. soehngenii at Creative Biolabs?
A. soehngenii Related Products at Creative Biolabs
We supply a variety of A. soehngenii strains of different preservation numbers as below. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
|
CAT
|
Product Name
|
Product Overview
|
Price
|
|
LBSX-0522-GF58
|
Anaerobutyricum soehngenii; 17630
|
A. soehngenii L2-7 is an anaerobe, mesophilic, Gram-positive bacterium that forms circular colonies and was isolated from Infant, faecal sample.
|
Inquiry
|
|
LBSX-0522-GF59
|
Anaerobutyricum soehngenii; 109238
|
A. soehngenii is an anaerobe, mesophilic, Gram-positive bacterium that forms circular colonies and was isolated from pig faeces.
|
Inquiry
|
Brochures
A. soehngenii plays an important role in metabolic syndrome disease and can be developed as promising potential therapeutic probiotics. If you are interested in our A. soehngenii related services or products, Creative Biolabs is happy to discuss with you and determine the most effective solution for you. Please feel free to contact us for further information.
FAQs
What are the key benefits of using A. soehngenii as a probiotic in metabolic health?
A. soehngenii is known for its ability to produce butyrate, a short-chain fatty acid that plays a crucial role in maintaining gut health. Butyrate enhances the integrity of the intestinal barrier, reduces inflammation, and improves insulin sensitivity. These properties make A. soehngenii particularly beneficial for managing metabolic disorders such as obesity and type 2 diabetes.
What unique features make A. soehngenii a superior choice for next-generation probiotics?
A. soehngenii stands out due to its robust production of butyrate, a short-chain fatty acid that plays a vital role in gut health. Butyrate enhances intestinal barrier integrity, reduces inflammation, and supports metabolic health. These unique features make A. soehngenii a powerful probiotic for managing conditions like metabolic syndrome and inflammatory bowel diseases.
What methodologies are used to develop A. soehngenii as a next-generation probiotic?
The development of A. soehngenii as a next-generation probiotic involves advanced genomic sequencing, metabolic profiling, and clinical trials. These methodologies help in identifying and characterizing beneficial strains, assessing their safety and efficacy, and understanding their mechanisms of action. Controlled production techniques ensure the stability and viability of the probiotic strains during administration.
What services are included in the A. soehngenii probiotics discovery package, and how do they benefit researchers?
The A. soehngenii probiotics discovery package includes strain isolation, genomic sequencing, functional assays, and metabolic profiling. These services provide researchers with comprehensive data to identify and characterize high-potential probiotic strains. The package ensures that only the most effective and safe strains are selected for further development, accelerating the research process and increasing the likelihood of successful probiotic products.
Resources
Reference
-
Li, L.; et al. The gut microbiota and its products: Establishing causal relationships with obesity related outcomes. Obes Rev. 2021, 22: e13341.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
